Physician profile
Marcus Mason
NPI 1033181854
$4,102.75
in general payments reported to CMS, 2019-2025
15 companies · $515 in 2025
The $515 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $89.45 · 2021: $390 · 2022: $766 · 2023: $598 · 2024: $751 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.39 |
| Education | $141.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $687.46 | 2019-2024 | Collagenase Santyl, Versajet, Acticoat 4" X 4" |
| Avanir Pharmaceuticals, INC. | $612.39 | 2019-2022 | |
| Ucb, INC. | $399.28 | 2019-2025 | Briviact |
| Neurocrine Biosciences, INC. | $388.72 | 2019-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $370.81 | 2021-2023 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $244.96 | 2022-2024 | Farxiga |
| Sunovion Pharmaceuticals INC. | $243.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $240.06 | 2023-2024 | Austedo Xr |
| Sk Life Science, INC. | $230.36 | 2022-2023 | Xcopri |
| Boston Scientific Corporation | $155.76 | 2025 | Watchman Flx |
| Medtronic, INC. | $141.70 | 2025 | |
| Greenwich Biosciences, INC. | $118.16 | 2019 | |
| Argenx US, INC. | $97.41 | 2025 | Vyvgart |
| Astellas Pharma US INC | $89.45 | 2020 | |
| Jazz Pharmaceuticals INC. | $82.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.